1. In Vivo
  2. >>Outlook
  3. >>Outlook Archive

Humira Biosimilars Prepare For US Competition In 2023

Landmark LOE Opportunity Looms, With Multiple Adalimumab Launches Expected

 
• By Dave Wallace

The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.  

Starter's Orders
Multiple Humira biosimilars are on the starting blocks awaiting launch in 2023 • Source: Shutterstock

With long-awaited biosimilar competition toAbbVie Inc.’s top-selling Humira (adalimumab) brand finally expected to hit the US in 2023, the off-patent industry is bracing for its biggest ever loss-of-exclusivity opportunity.

While Humira finally lost its crown as the world’s top-selling drug last year – unseated only by Pfizer Inc./

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Outlook Archive

More from Outlook

Investor Optimism Ahead As Big Medtech Proves ‘It’s All About Value’

 
• By Ashley Yeo

Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy

 
• By Joseph Haas

Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.

Big Pharma Headcounts: Obesity Leaders Bulk Up As Others Go Lean

 
• By Andrew McConaghie

As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.